Business
Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference
SAN DIEGO, Nov. 20, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop
About this update from Cardiff Oncology, Inc.
[{"type":"text","content":"SAN DIEGO, Nov. 20, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a fireside chat and 1x1 investor meetings at the 35th Annual Piper Sandler Healthcare Conference, which is taking place at the Lotte New York Palace in New York from November 28-30, 2023.\nDetails of the fireside chat can be found below.\nPresenter: Mark Erlander, CEODate: 11/29/2023Time: 10:00 – 10:25 AM ET in Soho Track\nInterested parties can register for and access the live webcast for Piper Sandler by visiting the \"Events\" section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation.\nAbout Cardiff Oncology, Inc.\nCardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.\nCardiff Oncology Contact:James LevineChief Financial [email protected]\nInvestor Contact:Kiki Patel, PharmD Gilmartin [email protected]\nMedia Contact:Richa KumariTaft Communications551 344-5592 [email protected]\n\n \n\n\n\n\n View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiff-oncology-to-present-at-the-35th-annual-piper-sandler-healthcare-conference-301991867.html\nSOURCE Cardiff Oncology, Inc.","length":4434,"tagName":"div"}]